Ironwood Pharmaceuticals, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; unaudited. Ironwood is a biopharmaceutical company whose marketed product is linaclotide, sold in the U.S. as LINZESS and in certain other markets as CONSTELLA. U.S. commercialization is shared with Actavis.
Financial highlights
Amounts below are in millions, except per-share data.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Collaborative arrangements revenue | $28.9 | $14.6 |
| Total costs and expenses | $57.0 | $59.0 |
| Operating loss | $(28.1) | $(44.4) |
| Net loss | $(33.2) | $(49.6) |
| Net loss per share, basic and diluted | $(0.24) | $(0.38) |
| Net cash used in operating activities | $(35.8) | $(57.9) |
- Revenue increased 98%, primarily reflecting an approximately $16.8 million increase in Ironwood’s U.S. LINZESS profit share. The company recorded $17.4 million of U.S. LINZESS share profit, versus $0.4 million a year earlier.
- Other revenue movements included approximately $0.8 million more AstraZeneca license revenue, partly offset by lower API shipments to licensing partners and lower milestone revenue.
- R&D expense was $26.6 million, down 2%; SG&A was $30.3 million, up 1%. Lower R&D costs included a $4.3 million reimbursement from Actavis for certain prior-period manufacturing costs; increased external linaclotide development costs partly offset savings.
- At March 31, cash and cash equivalents were $63.7 million and available-for-sale securities were $152.2 million, totaling $215.9 million in unrestricted liquid resources. Operating cash use was partly offset by $19.8 million of net investing cash inflow, largely reflecting securities maturities net of purchases.
- Total assets were $305.5 million and stockholders’ equity was $68.2 million. Notes payable were approximately $171.4 million; the notes bear 11% annual interest. The company made $2.3 million of principal payments in the quarter and expected approximately $13.2 million of principal due within the following 12 months.
Changes, outlook and risks
- Compared with Q1 2014, revenue nearly doubled and net loss narrowed by $16.4 million. The comparison also reflects $4.3 million of workforce-reduction charges in Q1 2014, with no such charge in Q1 2015.
- Management expected available cash and investments to fund projected operating needs for at least the next 12 months, while cautioning that actual cash needs could differ. The company expected continued losses and substantial R&D and commercialization spending; it provided no specific revenue or earnings guidance in the supplied filing text.
- Key programs included Phase III linaclotide trials in Japan and China and a U.S. Phase III trial of a 72 mcg dose for CIC. Ironwood also advanced GI and soluble guanylate cyclase programs. In March 2015, it agreed to co-promote Exact Sciences’ Cologuard under an initial one-year agreement; the arrangement had no significant Q1 results impact.
- Commercial results depend heavily on LINZESS adoption, reimbursement, execution with Actavis and partner performance. Almirall had suspended German CONSTELLA commercialization in 2014 after failing to agree on reimbursement pricing.
- Ironwood relies on external manufacturers and partners for linaclotide production and distribution. Development, regulatory, safety, supply, pricing and reimbursement outcomes remain uncertain. The company reported an accumulated deficit of approximately $1.0 billion and expected continued net losses.
- The 11% debt and payment structure create financing risk: quarterly payments are tied to U.S. LINZESS sales, and Ironwood must cover any shortfall from general funds. Management also noted potential variability in estimates of LINZESS sales used in debt accounting.
Important facts for investors to verify
- Whether U.S. LINZESS demand and profit share continue to grow, and how commercial costs and partner settlements affect reported revenue.
- Whether the $215.9 million of unrestricted cash and securities remains adequate against operating cash burn, planned development spending and debt payments.
- Progress and outcomes of linaclotide clinical and post-marketing programs, including pediatric studies, and the development pipeline.
- Partner execution, manufacturing capacity, product safety, and reimbursement and pricing developments—especially in Europe.
- The assumptions underlying the debt’s sales-linked repayment schedule and the expected $13.2 million of principal payments over the following 12 months.